GSK.BA : Summary for GLAXOSMITHKLINE CEDEAR EACH REP - Yahoo Finance

U.S. Markets closed

GLAXOSMITHKLINE CEDEAR EACH REP (GSK.BA)


Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
154.550.00 (0.00%)
At close: 1:30 PM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close154.55
Open154.55
Bid154.55 x
Ask154.55 x
Day's Range154.55 - 154.55
52 Week Range154.55 - 154.55
Volume10,360
Avg. Volume450
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • TheStreet.com2 days ago

    How to Buy GlaxoSmithKline at a 15% Discount

    Investors seeking more returns can not only get some yield, but also healthy dividends from buying options on stocks. Those who are seeking additional opportunities can purchase GlaxoSmithKline (GSK),

  • GlaxoSmithKline PLC (ADR) (GSK) Wins Approval Of Its Asthma Drug Nucala
    Insider Monkey2 days ago

    GlaxoSmithKline PLC (ADR) (GSK) Wins Approval Of Its Asthma Drug Nucala

    The National Institute for Health and Care Excellence (NICE) has confirmed the approval of a new injectable asthma drug from GlaxoSmithKline PLC (ADR) (NYSE:GSK). Nucala, a first-in-class antibody treatment had earlier suffered a major setback of rejection, which had been occasioned by cost-effectiveness concerns. NICE had also claimed that the drug would be used in less […]

  • Investopedia2 days ago

    Glaxo and Innoviva Get Positive News (GSK, INVA)

    Glaxo and Innoviva are moving higher on the heels of positive news in both Europe and Japan for a COPD drug.